Figure 2From: Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: a phase I trial Progression-free survival (PFS) and overall survival (OS) (n = 12). The median PFS and OS were 73 days and 328 days, respectively. Back to article page